Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by PGGM Investments

PGGM Investments cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,029 shares of the biopharmaceutical company’s stock after selling 20,613 shares during the quarter. PGGM Investments’ holdings in Regeneron Pharmaceuticals were worth $31,644,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in REGN. FMR LLC boosted its position in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after purchasing an additional 669,517 shares during the period. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 76,169.5% in the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after purchasing an additional 590,314 shares during the period. abrdn plc boosted its position in shares of Regeneron Pharmaceuticals by 552.8% in the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after purchasing an additional 186,215 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Regeneron Pharmaceuticals by 129.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock valued at $190,170,000 after purchasing an additional 122,103 shares during the period. Finally, TD Asset Management Inc boosted its position in shares of Regeneron Pharmaceuticals by 64.4% in the 3rd quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company’s stock valued at $148,353,000 after purchasing an additional 70,628 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the sale, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now owns 18,282 shares in the company, valued at $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the sale, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $7.48 during mid-day trading on Friday, hitting $883.20. The stock had a trading volume of 505,652 shares, compared to its average volume of 431,865. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a market cap of $96.94 billion, a price-to-earnings ratio of 25.42, a P/E/G ratio of 2.56 and a beta of 0.11. The company has a 50 day simple moving average of $948.00 and a 200 day simple moving average of $893.63. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $10.96 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the company. TD Cowen upped their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Finally, Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $977.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.